Keyphrases
Hematopoietic Stem Cells
85%
Pediatric
50%
Acute Myeloid Leukemia
40%
Graft-versus-host Disease (GvHD)
40%
Self-renewal
34%
Myelodysplastic Syndrome
29%
MLL-ENL
27%
Palliative Care
27%
Myeloablative
27%
Pediatric Leukemia
27%
Bone Marrow Transplantation
27%
Post-transplantation Cyclophosphamide (PTCy)
27%
Methamphetamine
27%
Inflammatory Cytokines
27%
Response Assessment in Neuro-Oncology Criteria
27%
ONC201
27%
Pten
27%
Stem Cell Response
27%
KMT2C
27%
Changes with Age
27%
Hemophagocytic Lymphohistiocytosis
27%
Isocitrate Dehydrogenase 1 (IDH1)
27%
Neonatal Development
27%
Pilocytic Astrocytoma
27%
IDH-mutant Glioma
27%
Multi-institutional Study
27%
BRAF Alteration
27%
Acute Appendicitis
27%
Genomic Landscape
27%
Chemotherapy
27%
FMS-like Tyrosine Kinase 3 (FLT3)
27%
Selective Advantage
27%
Neuronal Apoptosis
27%
Nuclear Factor of Activated T Cells
27%
Stem Cell Self-renewal
27%
Gastrointestinal Ulcer
27%
Unrelated Cord Blood Transplantation
27%
H3K27M
27%
Calcineurin
27%
Death Pathway
27%
Fas Ligand
27%
Leukemia
27%
Diffuse Midline Glioma
27%
Sickle Cell Disease
27%
Phase I Trial
27%
Reduced-intensity Conditioning
27%
Central Nervous System Cancer
27%
High-grade Glioma
24%
Overall Response Rate
21%
NCCN Guidelines
18%
Medicine and Dentistry
Pediatrics
100%
Ganglioglioma
63%
Bone Marrow Transplantation
54%
Acute Graft Versus Host Disease
31%
Pilocytic Astrocytoma
27%
Acute Leukemia
27%
Symptomatic Treatment
27%
Cyclophosphamide
27%
Transplantation
27%
Cord Blood Stem Cell Transplantation
27%
Sickle-Cell Disease
27%
Phase I Trials
27%
Reduced Intensity Conditioning
27%
Intestine Ulcer
27%
Cord Blood
27%
Acute Myeloid Leukemia
27%
Hemophagocytic Syndrome
27%
Acute Appendicitis
27%
Central Nervous System Cancer
27%
Survival Rate
25%
Engraftment
23%
Surgery
22%
Cumulative Incidence
20%
Myelodysplastic Syndrome
20%
Leukemia
20%
Graft Versus Host Reaction
19%
Overall Survival
19%
Oncology
15%
Recurrent Disease
13%
Tumor Recurrence
13%
Myeloablative Conditioning
13%
Neoplasm
13%
Gene Expression
13%
Signal Transduction
13%
Hematopoietic Cell
13%
Neuro-Oncology
12%
Mycophenolate Mofetil
12%
Virus Infection
10%
Thiotepa
10%
Disease Free Survival
10%
Patient with Sickle Cell Disease
10%
Tumor Progression
9%
Exudate
9%
Hemophagocytosis
9%
Physical Disease by Body Function
9%
Microscopy
9%
Laparoscopic Surgery
9%
Medulloblastoma
9%
Graft Failure
6%
Event Free Survival
6%